General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded without agreement
Manufacturer:
Eisai Limited
Indication:
Insomnia
Last updated September 29, 2023
Nexviazyme (avalglucosidase alfa)
Status:
Concluded without agreement
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Late-Onset Pompe Disease
Last updated September 29, 2023
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
Atopic dermatitis
Last updated September 19, 2023
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Severe asthma, add-on maintenance treatment in adults and adolescents 12 years and older
Last updated September 15, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Clostridium difficile infection
Last updated September 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Differentiated thyroid carcinoma (DTC), locally advanced or metastatic, in adult patients who are radioactive iodine-refractory (RAI-R) or ineligible, that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy
Last updated September 14, 2023
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated August 21, 2023
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Psoriatic Arthritis
Last updated August 8, 2023
Status:
Concluded with an LOI
Manufacturer:
Incyte Biosciences Canada Corporation
Indication:
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, including DLBCL arising from low grade lymphoma, in adult patients who are not eligible for autologous stem cell transplant (in combination with lenalidomide)
Last updated August 8, 2023
Status:
Negotiations were not pursued
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Stage III or metastatic small cell lung cancer (SCLC) in adult patients who have progressed on or after platinum-containing therapy
Last updated August 4, 2023